Pharmacy and therapeutics Committee Updates

(From the November 2018 Issue of MedStat

The following actions were taken at the 9/6/18 Pharmacy & Therapeutics Committee meeting. For more information, contact Michael Storey at Michael.Storey@NationwideChildrens.org.

  • A pharmacist-driven IV to Oral Policy was APPROVED
  • The propofol Infusion guideline was RETIRED from policies & procedures
  • The following low-use medications were removed from formulary:
    • aluminum acetate
    • alprotinin
    • antharidin
    • carbinoxamine
    • chloramphenicol
    • chlorpheniramine
    • cocaine
    • dihydroergotamine
    • glipizide
    • homatropine hydrobromide
    • muromonab-CD3
    • ooprelvekin
    • procarbazine
    • rizatriptan
    • simiele’s hemostatic solution
    • sodium glycerophosphate
    • thalidomide
    • thiopental sodium
    • tiagabine
    • zolmatriptan
  • Kovanaze (Tetracaine 3% and Oxymetazoline 0.05%) nasal spray was ADDED to formulary with prescribing restrictions
  • Revisions to Asthma Rescue Oral Corticosteroid Administration policy was APPROVED.
  • The investigational drug card for hu3F8-Naxitamab was APPROVED.